Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Health

Prevalence of Parkinson’s Disease Expected to Rise to 12-17 Million by 2040

The prevalence of Parkinson’s disease is on the rise, with an estimated 12 million to 17 million people expected to be affected by 2040, according to a recent three-paper series in The Lancet. The series addresses the current state of knowledge on the epidemiology of Parkinson’s disease, recent advances in understanding its pathogenesis, and the latest evidence supporting optimal medical, surgical, and physical treatment.

Parkinson’s disease, the second most common neurodegenerative disorder, is characterized by progressive asymmetric slowness of movement, rigidity, tremor, gait disturbance, and a wide range of non-motor symptoms. Its etiology involves both genetic and environmental risk factors, making it a multi-factorial condition.

Despite the increasing public health burden, current treatment strategies primarily focus on symptom management. There is an urgent need for disease-modifying treatments to prevent the development of the most disabling refractory symptoms, such as gait and balance difficulties, cognitive impairment and dementia, and speech and swallowing problems.

With increasing life expectancies and fewer competing causes of death, the prevalence of Parkinson’s disease is expected to grow to 12 million to 17 million people by 2040. This rise will place additional strain on health systems globally, particularly in low-income and middle-income countries where availability of treatments and supporting therapy is lowest. Even in high-income countries, minority ethnic groups and those in rural areas face challenges in accessing care.

Diagnosing Parkinson’s disease, especially in its early stages, presents difficulties that hinder effective care. There is a significant need for a better understanding of the specific needs of minority ethnic patients, whose clinical manifestations and associated morbidities are still poorly described.

The pathogenesis of Parkinson’s disease remains largely elusive, as detailed in the first two papers of the series. While experts agree that it is an age-related disease with a multi-factorial cause, there are still questions surrounding its exact origins.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *